NZ593227A - Gene expression markers (MYBL2) for colorectal cancer prognosis - Google Patents

Gene expression markers (MYBL2) for colorectal cancer prognosis

Info

Publication number
NZ593227A
NZ593227A NZ593227A NZ59322707A NZ593227A NZ 593227 A NZ593227 A NZ 593227A NZ 593227 A NZ593227 A NZ 593227A NZ 59322707 A NZ59322707 A NZ 59322707A NZ 593227 A NZ593227 A NZ 593227A
Authority
NZ
New Zealand
Prior art keywords
colorectal cancer
mybl2
gene expression
human subject
clinical outcome
Prior art date
Application number
NZ593227A
Other languages
English (en)
Inventor
Wayne Cowens
Joffre B Baker
Kim Clark
James Hackett
Drew Watson
Soonmyung Paik
Original Assignee
Genomic Health Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Nsabp Foundation Inc filed Critical Genomic Health Inc
Publication of NZ593227A publication Critical patent/NZ593227A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ593227A 2006-01-11 2007-01-11 Gene expression markers (MYBL2) for colorectal cancer prognosis NZ593227A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75839206P 2006-01-11 2006-01-11
US80027706P 2006-05-12 2006-05-12
US81007706P 2006-05-31 2006-05-31
NZ569788A NZ569788A (en) 2006-01-11 2007-01-11 RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis

Publications (1)

Publication Number Publication Date
NZ593227A true NZ593227A (en) 2012-10-26

Family

ID=38257063

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ593227A NZ593227A (en) 2006-01-11 2007-01-11 Gene expression markers (MYBL2) for colorectal cancer prognosis
NZ569788A NZ569788A (en) 2006-01-11 2007-01-11 RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis
NZ593229A NZ593229A (en) 2006-01-11 2007-01-11 Gene expression markers (gadd45b) for colorectal cancer prognosis
NZ593228A NZ593228A (en) 2006-01-11 2007-01-11 Gene expression markers (inhba) for colorectal cancer prognosis
NZ593225A NZ593225A (en) 2006-01-11 2007-01-11 Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
NZ593224A NZ593224A (en) 2006-01-11 2007-01-11 Gene expression markers (fap) for colorectal cancer prognosis
NZ593226A NZ593226A (en) 2006-01-11 2007-01-11 Gene expression markers (efnb2) for colorectal cancer prognosis

Family Applications After (6)

Application Number Title Priority Date Filing Date
NZ569788A NZ569788A (en) 2006-01-11 2007-01-11 RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis
NZ593229A NZ593229A (en) 2006-01-11 2007-01-11 Gene expression markers (gadd45b) for colorectal cancer prognosis
NZ593228A NZ593228A (en) 2006-01-11 2007-01-11 Gene expression markers (inhba) for colorectal cancer prognosis
NZ593225A NZ593225A (en) 2006-01-11 2007-01-11 Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
NZ593224A NZ593224A (en) 2006-01-11 2007-01-11 Gene expression markers (fap) for colorectal cancer prognosis
NZ593226A NZ593226A (en) 2006-01-11 2007-01-11 Gene expression markers (efnb2) for colorectal cancer prognosis

Country Status (14)

Country Link
US (10) US7695913B2 (enExample)
EP (9) EP2412823B1 (enExample)
JP (7) JP5297202B2 (enExample)
KR (1) KR20090003178A (enExample)
AU (1) AU2007204826B2 (enExample)
BR (1) BRPI0706511A2 (enExample)
CA (1) CA2636984A1 (enExample)
DK (1) DK1974058T3 (enExample)
ES (1) ES2491222T3 (enExample)
IL (1) IL192794A (enExample)
MX (1) MX2008008973A (enExample)
NO (1) NO20083461L (enExample)
NZ (7) NZ593227A (enExample)
WO (1) WO2007082099A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
DK1974058T3 (da) * 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
AU2007253740A1 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
AU2008231575A1 (en) 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
US20090123920A1 (en) * 2007-11-08 2009-05-14 Maher Albitar Jak2 mutations
ES2332167B1 (es) * 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2009123634A1 (en) * 2008-04-02 2009-10-08 Regents Of The University Of California Systems and methods for predicting response of biological samples
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009246398A1 (en) 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
US20100029748A1 (en) * 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
MX2011011571A (es) * 2009-05-01 2012-02-13 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
KR101857462B1 (ko) 2010-08-13 2018-05-14 소마로직, 인크. 췌장암 바이오마커 및 그것의 용도
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
KR20130115250A (ko) 2010-09-15 2013-10-21 알막 다이아그노스틱스 리미티드 암에 대한 분자적 진단 테스트
CA2825218A1 (en) * 2011-01-25 2012-08-02 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
AU2012330817A1 (en) * 2011-11-04 2014-05-22 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
MX2014006404A (es) 2011-11-28 2015-03-03 Institució Catalana De Recerca I Estudis Avançats Metodos y kits para el pronostico del cancer colorrectal.
US10519506B2 (en) 2011-12-22 2019-12-31 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer
WO2013104990A1 (en) * 2012-01-09 2013-07-18 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
HK1201881A1 (en) 2012-01-31 2015-09-11 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2013150167A2 (es) 2012-04-03 2013-10-10 Servicio Andaluz De Salud Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
ES2475366B1 (es) * 2012-12-10 2015-05-05 Fundación Imdea Alimentación Métodos y kits para el pronóstico del cáncer colorrectal
US9994908B2 (en) 2013-03-14 2018-06-12 Abbott Molecular Inc. Materials and methods for assessment of colorectal adenoma
AR096507A1 (es) * 2013-05-30 2016-01-13 Fundació Institució Catalana De Recerca I Estudis Avançats Métodos y kits para el pronóstico del cáncer colorrectal
US10185809B1 (en) * 2013-10-15 2019-01-22 Iqvia Inc. Patient projection methodology
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
CA2943827A1 (en) * 2014-03-28 2015-10-01 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
EP3210143B1 (en) 2014-10-24 2020-12-09 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CA2965442C (en) 2014-10-24 2024-06-25 Koninklijke Philips N.V. Assessment of tgf-b cellular signaling pathway activity using mathematical modelling of target gene expression
ES2838923T3 (es) 2014-10-24 2021-07-02 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta a tratamiento usando múltiples actividades de la ruta de señalización celular
DE112014007209T5 (de) 2014-11-25 2017-08-03 Mitsubishi Electric Corporation Pneumatischer Antrieb
WO2016089928A1 (en) * 2014-12-01 2016-06-09 Weitz Andrew C Methods for treating and assessing tumor invasion and metastasis
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation Detecting esophageal disorders
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
CA2982169A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2016208776A1 (ja) * 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
BR112018002848A2 (pt) 2015-08-14 2018-11-06 Koninklijke Philips Nv método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
CN109477147A (zh) 2016-05-10 2019-03-15 梅约医学教育与研究基金会 用于皮肤癌分期和治疗的方法和材料
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
WO2018224731A1 (en) * 2017-06-05 2018-12-13 Ls Cancerdiag Oy A method for determining whether a subject is at risk to develop cancer and tools related thereto
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
US11549152B2 (en) 2018-03-08 2023-01-10 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
KR102007450B1 (ko) * 2018-05-31 2019-08-05 한국과학기술연구원 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커
AU2019310636B2 (en) 2018-07-25 2025-06-26 Mayo Foundation For Medical Education And Research Gene signatures for predicting metastasis of melanoma and patient prognosis
US12370240B2 (en) 2018-11-28 2025-07-29 Genascence Corporation Methods and compositions for treating osteoarthritis
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
CN110257518B (zh) * 2019-07-01 2022-08-02 复旦大学附属中山医院 一种用于预测转移性结直肠癌转化治疗疗效的基因集
US12057959B2 (en) * 2019-12-31 2024-08-06 Mcafee, Llc Device identification
KR102263984B1 (ko) * 2020-02-21 2021-06-11 재단법인 아산사회복지재단 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법
KR102535150B1 (ko) * 2020-04-14 2023-05-23 주식회사 베르티스 암의 예후 예측용 조성물
AU2021263680A1 (en) * 2020-04-29 2022-11-24 Freenome Holdings, Inc. RNA markers and methods for identifying colon cell proliferative disorders
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112322730B (zh) * 2020-10-16 2023-04-18 上海市第一人民医院 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用
EP4026918A1 (en) 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN113667673B (zh) * 2021-07-15 2024-02-06 武汉血液中心 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用
KR20230059642A (ko) * 2021-10-26 2023-05-03 사회복지법인 삼성생명공익재단 miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도
CN116735874B (zh) * 2022-03-11 2025-09-23 上海市免疫学研究所 结直肠癌肿瘤边界细胞亚群标志物组合及其应用
WO2024035653A1 (en) * 2022-08-06 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
EP1084273A1 (en) * 1998-06-06 2001-03-21 Genostic Pharma Limited Probes used for genetic profiling
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000024940A1 (en) 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
EP0999016B1 (en) * 1998-11-06 2001-07-11 Temco S. R. L. Cutter for cross cutting of webs
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
EP1265582A2 (en) * 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001041815A2 (en) 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
US7029677B2 (en) * 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
US20050282157A1 (en) 2000-04-06 2005-12-22 Alexander Olek Diagnosis of diseases associated with dna replication
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
US20020110832A1 (en) 2000-08-03 2002-08-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002012328A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030166064A1 (en) * 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2002024956A2 (en) 2000-09-19 2002-03-28 Whitehead Institute For Biomedical Research Genetic markers for tumors
AU2002246519A1 (en) * 2000-11-20 2002-08-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002074156A2 (en) * 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2002311903A1 (en) * 2001-05-09 2002-11-18 University Hospitals Of Cleveland Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
KR20040064275A (ko) * 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
WO2003041562A2 (en) * 2001-11-14 2003-05-22 Whitehead Institute For Biomedical Research Molecular cancer diagnosis using tumor gene expression signature
WO2003050243A2 (en) 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US20070166704A1 (en) * 2002-01-18 2007-07-19 Fei Huang Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
CA2498418A1 (en) * 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
JP2007507204A (ja) * 2003-07-29 2007-03-29 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20060195266A1 (en) * 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2562835A1 (en) 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
US20080032293A1 (en) 2004-07-15 2008-02-07 The University Of North Carolina At Chapel Hill Housekeeping Genes And Methods For Identifying Same
US20060183893A1 (en) 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
EP1910557A2 (en) 2005-04-07 2008-04-16 Chiron Corporation Cancer-related genes
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
DK1974058T3 (da) 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
US20100009905A1 (en) 2006-03-24 2010-01-14 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer
US20090258795A1 (en) * 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8067178B2 (en) * 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
MX2011011571A (es) * 2009-05-01 2012-02-13 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.

Also Published As

Publication number Publication date
JP5486664B2 (ja) 2014-05-07
US20110039272A1 (en) 2011-02-17
US20120171688A1 (en) 2012-07-05
US8153379B2 (en) 2012-04-10
US20110097759A1 (en) 2011-04-28
EP2412822A1 (en) 2012-02-01
EP2412821B1 (en) 2014-09-17
EP2377950A1 (en) 2011-10-19
WO2007082099A3 (en) 2008-01-17
JP2009523028A (ja) 2009-06-18
US20110039271A1 (en) 2011-02-17
EP1974058B1 (en) 2014-06-11
US20110039269A1 (en) 2011-02-17
JP2013226150A (ja) 2013-11-07
US8273537B2 (en) 2012-09-25
EP2412823A1 (en) 2012-02-01
US8153378B2 (en) 2012-04-10
US20130102492A1 (en) 2013-04-25
EP2412824A1 (en) 2012-02-01
JP5486718B2 (ja) 2014-05-07
AU2007204826B2 (en) 2013-01-10
EP2412823B1 (en) 2014-09-03
ES2491222T3 (es) 2014-09-05
MX2008008973A (es) 2008-11-26
US20100190173A1 (en) 2010-07-29
JP2013215201A (ja) 2013-10-24
HK1120089A1 (en) 2009-03-20
US8153380B2 (en) 2012-04-10
EP2412824B1 (en) 2014-10-08
US20090291434A1 (en) 2009-11-26
JP5486720B2 (ja) 2014-05-07
JP5297202B2 (ja) 2013-09-25
NO20083461L (no) 2008-10-10
JP2013226151A (ja) 2013-11-07
US20110111421A1 (en) 2011-05-12
WO2007082099A2 (en) 2007-07-19
EP1974058A2 (en) 2008-10-01
KR20090003178A (ko) 2009-01-09
NZ593224A (en) 2012-10-26
NZ569788A (en) 2011-08-26
JP5486717B2 (ja) 2014-05-07
EP2407553A1 (en) 2012-01-18
JP2013176398A (ja) 2013-09-09
US8029995B2 (en) 2011-10-04
NZ593225A (en) 2012-10-26
NZ593226A (en) 2012-10-26
JP2013074894A (ja) 2013-04-25
BRPI0706511A2 (pt) 2011-03-29
US8026060B2 (en) 2011-09-27
IL192794A0 (en) 2009-02-11
IL192794A (en) 2013-07-31
NZ593228A (en) 2012-10-26
AU2007204826A1 (en) 2007-07-19
JP5486719B2 (ja) 2014-05-07
NZ593229A (en) 2012-10-26
EP2412821A1 (en) 2012-02-01
CA2636984A1 (en) 2007-07-19
EP2412820A1 (en) 2012-02-01
JP2013223503A (ja) 2013-10-31
US8367345B2 (en) 2013-02-05
DK1974058T3 (da) 2014-09-01
US8198024B2 (en) 2012-06-12
EP2400036A1 (en) 2011-12-28
US20110039270A1 (en) 2011-02-17
EP2377950B1 (en) 2014-09-17
US7695913B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
NZ593227A (en) Gene expression markers (MYBL2) for colorectal cancer prognosis
Han et al. Long intergenic non‐coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder
EP3571322B9 (en) Molecular subtyping, prognosis, and treatment of bladder cancer
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
Goh et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
NZ719474A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
NZ599194A (en) Methods to predict clinical outcome of cancer
US20090098538A1 (en) Prognostic and diagnostic method for disease therapy
EP2288741A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
CA2660857A1 (en) Prognostic and diagnostic method for disease therapy
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
Lee et al. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs
US20220213557A1 (en) Non-coding rna for subtyping of bladder cancer
WO2008103971A3 (en) Prostate cancer survival and recurrence
Sand et al. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study
WO2005001138A3 (en) Breast cancer survival and recurrence
Jiang et al. LncRNA FLVCR1-AS1 accelerates osteosarcoma cells to proliferate, migrate and invade via activating wnt/β-catenin pathway
Melendez-Zajgla et al. The role of lncRNAs in the stem phenotype of pancreatic ductal adenocarcinoma
Lin et al. Long non-coding RNA TTN-AS1 serves as a competing endogenous rna of mir-195 to facilitate clear cell renal cell carcinoma progression
WO2011160118A2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
WO2010030167A3 (en) Method of detection and diagnosis of oral and nasopharyngeal cancers
EP2550534A1 (en) Prognosis of oesophageal and gastro-oesophageal junctional cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JAN 2014 BY CPA GLOBAL

Effective date: 20130405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JAN 2017 BY CPA GLOBAL

Effective date: 20131129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20171219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2023 BY COMPUTER PACKAGES INC

Effective date: 20211217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20221217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217